Eisai Acquires Four Oncology-Related Products from Ligand
Eisai Co., Ltd.
Tokyo, Japan and Teaneck, New Jersey, United States- Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito) and Eisai Inc. (Headquarters: New Jersey, Chairman and CEO: Hajime Shimizu) today announce that on September 7 (U.S. Eastern Time), the companies signed a product acquisition agreement with Ligand Pharmaceuticals (Headquarters: California, Chairman and interim CEO: Henry F. Blissenbach) for exclusive global rights for their four oncology-related products, ONTAK (denileukin diftitox), Targretin (bexarotene) capsules, Targretin (bexarotene) gel 1% and Panretin (alitretinoin) gel 0.1%.
This agreement will enable Eisai to succeed the global marketing of the four acquired products. In addition, certain Ligand personnel will be offered employment by Eisai Inc. The cost for this agreement is U.S. $205 million.
There are various needs of patients exists in oncology and new innovation in this field is progressed day by day. Oncology is also positioned as one of Eisai's long-standing therapeutic areas of focus per its 5th mid-term business plan "Dramatic Leap Plan". The company believes that the strategic acquisition of these four products will be a promising approach prior to the market entry by its original compound.
Eisai is progressing with the global oncology business development with a number of approaches including new drug development and strengthening the company's marketing and sales operations. Through enhancement in the oncology product lines, the company wishes to create value for patients, contributing to the benefits of patients and their families.
The transaction is subject to governmental approvals and is expected to close after certain preparation period.
[Please refer to the following notes for the product information, glossary and Eisai's anticancer compounds in development. ]
<Note to Editors>
Eisai's anticancer compounds in development (after phase I)